NO20070127L - Fremgangsmate for behandling av granuloma annulare eller sarkoid - Google Patents

Fremgangsmate for behandling av granuloma annulare eller sarkoid

Info

Publication number
NO20070127L
NO20070127L NO20070127A NO20070127A NO20070127L NO 20070127 L NO20070127 L NO 20070127L NO 20070127 A NO20070127 A NO 20070127A NO 20070127 A NO20070127 A NO 20070127A NO 20070127 L NO20070127 L NO 20070127L
Authority
NO
Norway
Prior art keywords
sarcoid
procedure
treatment
granuloma
annular
Prior art date
Application number
NO20070127A
Other languages
English (en)
Inventor
Bernard S Goffe
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20070127L publication Critical patent/NO20070127L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Oppfinnelsen tilveiebringer en fremgangsmåte for å lindre en granuloma annulare eller en sarkoid sykdom ved å administiere til en pasient som har sykdommen en terapeutisk effektiv mengde av en LFA-1 -antagonist.
NO20070127A 2004-06-09 2007-01-08 Fremgangsmate for behandling av granuloma annulare eller sarkoid NO20070127L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57876804P 2004-06-09 2004-06-09
US57909604P 2004-06-10 2004-06-10
PCT/US2005/020342 WO2005123777A2 (en) 2004-06-09 2005-06-08 Method of treating granuloma annulare or sarcoid

Publications (1)

Publication Number Publication Date
NO20070127L true NO20070127L (no) 2007-01-08

Family

ID=35355731

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070127A NO20070127L (no) 2004-06-09 2007-01-08 Fremgangsmate for behandling av granuloma annulare eller sarkoid

Country Status (11)

Country Link
US (1) US7396530B2 (no)
EP (1) EP1756163A2 (no)
JP (1) JP2008507592A (no)
AU (1) AU2005254980A1 (no)
BR (1) BRPI0511305A (no)
CA (1) CA2568570A1 (no)
IL (1) IL179557A0 (no)
MX (1) MXPA06014354A (no)
NO (1) NO20070127L (no)
RU (1) RU2006146939A (no)
WO (1) WO2005123777A2 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
CA2702984C (en) 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
EP3632444A3 (en) * 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
RU2671516C1 (ru) * 2018-01-10 2018-11-01 Федеральное государственное бюджетное военное образовательное учреждение высшего образования Военно-медицинская академия имени С.М. Кирова Министерства обороны Российской Федерации (ВМедА) Способ лечения кольцевидной гранулемы

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002869A (en) * 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
US5071964A (en) * 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US5147637A (en) 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
NO900155L (no) 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
CA2008368C (en) 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
EP0462184A4 (en) 1989-03-09 1992-01-08 Dana Farber Cancer Institute Method of treating viral infections using lfa-1
ES2097747T3 (es) 1989-03-09 1997-04-16 Blood Res Center Molecula de adhesion intercelular 2 y sus ligandos de union.
WO1990013281A2 (en) 1989-04-28 1990-11-15 Baylor College Of Medicine Method of suppressing hiv infection
EP0432249B1 (en) 1989-06-02 1996-09-25 The Johns Hopkins University School Of Medicine Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore
US5324510A (en) * 1989-09-01 1994-06-28 Boehringer Ingelheim Pharmaceuticals, Inc. Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9009549D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
WO1991018011A1 (en) 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
EP0610298A1 (en) 1991-10-01 1994-08-17 The General Hospital Corporation Preventing allograft rejection with antibodies to adhesion molecules
AU2777092A (en) * 1991-10-04 1993-05-03 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Treatment of ocular inflammation by blockage of cell adhesion molecules
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
GB2266664A (en) 1992-04-28 1993-11-10 Pierre Francois Piguet Monoclonal antibodies for prophylaxis and treatment of pulmonary fibrosis
CA2140933A1 (en) * 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
AU731817C (en) * 1996-11-27 2001-11-01 Genentech Inc. Humanized anti-CD11a antibodies
FR2763072B1 (fr) 1997-05-12 1999-11-05 Pasteur Merieux Serums Vacc Utilisation d'un anticorps monoclonal anti-lfa1 en transplantation renale
CO5140104A1 (es) * 1999-02-16 2002-03-22 Novartis Ag Derivados de mevinolina y preparacion farmaceuticas que los contienen
AR030817A1 (es) * 2000-10-02 2003-09-03 Novartis Ag Derivados de diazacicloalcanodiona

Also Published As

Publication number Publication date
US7396530B2 (en) 2008-07-08
JP2008507592A (ja) 2008-03-13
CA2568570A1 (en) 2005-12-29
WO2005123777A2 (en) 2005-12-29
RU2006146939A (ru) 2008-07-20
IL179557A0 (en) 2007-05-15
EP1756163A2 (en) 2007-02-28
BRPI0511305A (pt) 2007-12-04
MXPA06014354A (es) 2007-02-19
US20060013818A1 (en) 2006-01-19
AU2005254980A1 (en) 2005-12-29
WO2005123777A3 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
BR0314760A (pt) Compostos orgânicos
BRPI0510274A (pt) epìtopos relacionados à doença celìaca
NO20070906L (no) Fremgangsmate for behandling av hyperfosfatanemi ved anvendelse av lantanhydroksykarbonat
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
BRPI0416628A (pt) uso de compostos orgánicos
WO2008050329A3 (en) Novel sirnas and methods of use thereof
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
WO2007128802A3 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
NO20091296L (no) Fremgangsmate for behandling av slag med trombolytisk middel
NO20083561L (no) Forbindelser for behandling av inflammatoriske forstyrrelser
MA34133B1 (fr) Composes pour inhibiteurs de l'immunoproteasome
NO20083836L (no) N-hydroksyakrylamidforbindelser
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MA56187B1 (fr) Traitements de l'angio-oedème héréditaire
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
NO20076245L (no) Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner
NO20074252L (no) Forbindelser og anvendelser derav
WO2006106311A3 (en) Combination treatment methods for treating sex-hormone dependent disease and fertility treatment
NO20061818L (no) Fremgangsmate for a inhibere remnant lipoproteinproduksjon
DK1778837T3 (da) Behandling af neurodegenerative sygdomme ved anvendelse af SCD4-inhibitorer
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
NO20070061L (no) 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav
WO2007019153A3 (en) Methods for treating hypertension

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application